The first hemostasis kit combines two important surgical tools: Baxter's
human thrombin and Pfizer's GELFOAM
DEERFIELD, Ill., Dec. 17 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced the Food and Drug Administration approval of GELFOAM(R) Plus Hemostasis Kit (absorbable gelatin sponge, USP and human thrombin). GELFOAM Plus is the only available hemostasis kit that contains Pfizer's GELFOAM(R) brand plus Baxter's Thrombin (Human) for use in controlling bleeding during surgical procedures.
"Baxter is pleased about the agreement with Pfizer and FDA approval of this combination hemostasis product," said Ron Lloyd, vice president of Baxter's BioTherapeutics and Regenerative Medicine business. "This reflects our commitment to providing options for use in surgical procedures, providing our customers with convenience and potential cost savings by supplying two components in a single kit."
Baxter and Pfizer signed a marketing, supply and manufacturing agreement for GELFOAM Plus Hemostasis Kit. Under the terms of the agreement, Baxter is the exclusive distributor of GELFOAM Plus Hemostasis Kit. Pfizer will provide the sterile GELFOAM gelatin absorbable sponge and Baxter will assemble, distribute and promote the GELFOAM Plus Hemostasis Kit.
"The news of the FDA approval and agreement with Baxter is very promising for both companies," said David J. Engels, senior director, U.S. Diversified Products at Pfizer. "GELFOAM Plus will be well received in the surgical field as it provides a practical solution using the existing GELFOAM product with Baxter's human thrombin and has also been shown to be more effective for achieving hemostasis than the use of GELFOAM wetted with saline."
Pfizer's GELFOAM is indicated as a hemostatic device for surgical
procedures when control of capillary, venous and arteriolar bleeding by
pressure, ligature and conventional procedures is either ineffective or
|SOURCE Baxter Healthcare Corporation|
Copyright©2007 PR Newswire.
All rights reserved